• Bifidobacterium, FMT, and PET in HE Rats

  2026-09-23

  This study used [18F]PBR146 PET/CT to compare Bifidobacterium and fecal microbiota transplantation in rats with bile duct ligation-induced chronic hepatic encephalopathy. Global brain uptake and several behavioral and cytokine measures did not differ significantly, but regional imaging findings supported a neuroinflammation-reducing effect of Bifidobacterium that was not observed with FMT.

• Aprotinin Workflows for Protease-Controlled Research

  2026-09-23

  Aprotinin enables controlled, reversible suppression of trypsin, plasmin, and kallikrein in biochemical, inflammatory, and cardiovascular research models. This guide combines practical dosing logic, sample-handling workflows, GRO-seq-inspired quality controls, and troubleshooting strategies for more reproducible experiments.

• Localized BDNF Release in NMJ Assembly

  2026-09-22

  The reference study shows that skeletal muscle-derived BDNF is trafficked to actin-rich podosome-like structures, where calcium-dependent, spatially restricted release supports the earliest stages of neuromuscular junction assembly. Its combination of live imaging, targeted perturbations, and muscle-specific knockout experiments links BDNF localization and proteolytic processing to aneural and nerve-induced acetylcholine receptor clustering.

• BMS-777607: From MET Biology to Translational Models

  2026-09-22

  A mechanism-first guide to using BMS-777607 as a selective c-Met inhibitor across cancer metastasis models, MET-family biology, and exploratory hiPSC-derived platelet research.

• Reserpine (N1867): Practical Lab Workflow

  2026-09-21

  Reserpine (SKU N1867) provides a high-purity, characterized research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and troubleshooting while clarifying that the product is for research use only, not diagnostic, clinical, medical, or veterinary applications.

• Firefly Luciferase mRNA: Assay Workflow

  2026-09-21

  Build more interpretable transfection, gene expression, cell viability, and imaging studies with a chemically optimized bioluminescent reporter. This workflow connects practical handling of Firefly Luciferase mRNA with delivery benchmarking and translational mRNA research.

• Nutlin-3a and the Next Logic of p53 Translation

  2026-09-20

  Nutlin-3a offers a precise way to interrogate MDM2–p53 biology while opening a translational conversation about ferroptosis, migration, and treatment strategy in glioblastoma. This article connects target engagement with experimental design, model selection, and clinically relevant decision points.

• FITC Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-09-19

  This fluorescein-conjugated secondary antibody provides fluorescent detection of mouse IgG primary antibodies in immunofluorescence, microscopy, and flow cytometry workflows. It is intended for research assay development and optimization, not as a standalone reagent for detecting non-mouse immunoglobulins or as evidence of a validated clinical diagnostic procedure.

• BMPSB4 Activates Autophagy in Corticotroph PitNETs

  2026-09-18

  A 2024 study identifies BMPSB4 as a pharmacological agonist of deficient BMP4 signaling in corticotroph pituitary neuroendocrine tumors. Using transcriptomic, imaging, cellular, and animal-model evidence, the authors link BMP4/SMAD1/5/9 activation to autophagy-mediated tumor suppression and reduced ACTH and corticosterone output.

• Sodium Ascorbate: From ROS Biology to Translation

  2026-09-18

  A translational perspective on how Sodium Ascorbate can support reproducible ROS-driven cancer research, while biomarker-led models such as circulating GPNMB illustrate the requirements for moving from tumor-cell phenotypes toward precision study design.

• Cabozantinib (XL184) in RCC Research Workflows

  2026-09-17

  Cabozantinib (XL184) supports more than endpoint viability assays: it enables time-resolved studies of RTK suppression, angiogenesis, phosphoproteomic remodeling, and motility adaptation. This workflow translates acute-versus-chronic exposure findings into practical renal cell carcinoma and endothelial assay designs.

• Cabozantinib (XL184) RCC Research Workflow

  2026-09-17

  Build reproducible Cabozantinib experiments that separate acute kinase suppression from chronic adaptation in renal cell carcinoma. This workflow combines phosphoproteomics, MET validation, motility assays, and angiogenesis readouts to turn a multi-target inhibitor into a practical systems-biology tool.

• AAL-993: A Decision Framework for Angiogenesis Assays

  2026-09-16

  AAL-993 is a VEGF receptor inhibitor suited to mechanistically layered angiogenesis studies. This article shows how to connect receptor-level potency, endothelial phenotypes, tumor-model outcomes, and network-pharmacology insights without overstating cross-domain evidence.

• Angiotensin (1-7) Experimental Workflows

  2026-09-16

  Build reproducible Mas-receptor experiments with a defined heptapeptide sequence, practical dosing benchmarks, and assay-ready handling guidance. From renal fibrosis models to receptor-binding studies, this workflow connects mechanism, controls, and troubleshooting without overstating translational evidence.

• Reserpine (N1867): Practical Lab Workflow

  2026-09-15

  Reserpine (SKU N1867) provides a characterized research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and related neuropharmacology research. This guide addresses identity, solubility, storage, solution preparation, and QC; the compound is for research use only and should not be used for diagnostic, therapeutic, or medical applications.

8504 records 1/567 page Next 12345 下5页 Last page